Public Health Genomics Webinar
The Role of Cost-Effectiveness Analysis in Precision Medicine and Public Health Genomics
March 27, 2018, 10:00-11:30 am EST
CDC Chamblee Campus, Chamblee Campus Bldg 102 RM 2202
Free Registration is required. REGISTER NOW
Mark your Calendar to View the Webinar via Skype
Join by Phone: (885) 644-0229- Conference ID: 4390261
Scott Grosse, PhD
Health Economist,
National Center on Birth Defects and Developmental Disabilities,
Centers for Disease Control and Prevention
Cost-effectiveness analyses can be used to help understand the health and economic impacts of implementing new technologies. Dr. Grosse will provide an introduction to terminology and methods used in economic analyses. Examples of estimates of costs, effectiveness, and cost-effectiveness in public health and precision medicine will be presented, including ivacaftor treatment for cystic fibrosis, addition of conditions for newborn screening and Lynch syndrome screening of newly diagnosed colorectal cancers. He will discuss the role of cost-effectiveness and other criteria in prioritizing and evaluating public health activities in genomics and precision medicine.
Selected References:
- Whiting P et al. Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis.external icon Health Technol Assess. 2014 Mar;18(18):1-106
- Grosse SD, Khoury MJ. Epidemiology matters: peering inside the “black box” in economic evaluations of genetic testing.external icon Genet Med. 2016 Oct;18(10):963-5.
Page last reviewed: February 27, 2018
Content source: Office of Science (OS), Office of Genomics and Precision Public Health